Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing For Federal Agencies, 66034-66036 [2013-26276]
Download as PDF
<![CDATA[
66034
Federal Register / Vol. 78, No. 213 / Monday, November 4, 2013 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
TKELLEY on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of meeting of the
National Cancer Advisory Board.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
A portion of the meeting will be
closed to the public as indicated below
in accordance with the provisions set
forth in sections 552b(c)(4) and
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Cancer Institute, including
consideration of personnel
qualifications and performance and the
competence of individual investigators.
Additionally for the review of grant
applications and the discussions, that
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board; Ad hoc Subcommittee on
Global Cancer Research.
Open: December 9, 2013, 6:00 p.m. to 7:30
p.m.
Agenda: Discussion on Global Cancer
Research.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, Maryland
20814.
Contact Person: Dr. Edward Trimble,
Executive Secretary, NCAB Ad hoc
Subcommittee on Global Cancer Research,
National Cancer Institute, National Institutes
of Health, 9609 Medical Center Drive, Room
3W–562, Bethesda, MD 20892, (240) 276–
5796, trimblet@mail.nih.gov.
Name of Committee: National Cancer
Advisory Board; Ad hoc Subcommittee on
Communications.
Open: December 9, 2013, 7:45 p.m. to 9:15
p.m.
Agenda: Discussion on Communications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, Maryland
20814.
Contact Person: Dr. Lenora Johnson,
Executive Secretary, NCAB Ad hoc
VerDate Mar<15>2010
17:07 Nov 01, 2013
Jkt 232001
Subcommittee on Communications, National
Cancer Institute, National Institutes of
Health, 9606 Medical Center Drive, Room
2E–454, Bethesda, MD 20892, (240) 276–
6680, johnslen@mail.nih.gov.
Name of Committee: National Cancer
Advisory Board.
Open: December 10, 2013, 9:00 a.m. to 3:30
p.m.
Agenda: Program reports and
presentations; business of the Board.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 9606
Medical Center Drive, Room 7W–444,
Bethesda, MD 20892, (240) 276–6340.
Name of Committee: National Cancer
Advisory Board.
Closed: December 10, 2013, 3:30 p.m. to
5:00 p.m.
Agenda: Review intramural program site
visit outcomes. Discussion of confidential
and personnel issues. Review and evaluate
grant applications.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 9606
Medical Center Drive, Room 7W–444,
Bethesda, MD 20892, (240) 276–6340.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: NCAB:
deainfo.nci.nih.gov/advisory/ncab.htm where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS).
Dated: October 29, 2013.
Melanie Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–26253 Filed 11–1–13; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories and
Instrumented Initial Testing Facilities
Which Meet Minimum Standards To
Engage in Urine Drug Testing For
Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the Laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently certified
laboratories and IITF is published in the
Federal Register during the first week of
each month. If any laboratory or IITF
certification is suspended or revoked,
the laboratory or IITF will be omitted
from subsequent lists until such time as
it is restored to full certification under
the Mandatory Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov.
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 7–
1051, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
SUMMARY:
E:\FR\FM\04NON1.SGM
04NON1
Federal Register / Vol. 78, No. 213 / Monday, November 4, 2013 / Notices
drug and specimen validity tests on
urine specimens for federal agencies.
To become certified, an applicant
Laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a Laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITF in the applicant
stage of certification are not to be
considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A Laboratory or
IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following
Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Instrumented Initial Testing Facilities
(IITF)
None.
TKELLEY on DSK3SPTVN1PROD with NOTICES
Laboratories
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840/800–877–7016, (Formerly:
Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264
Aegis Analytical Laboratories, 345 Hill
Ave., Nashville, TN 37210, 615–255–
2400, (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc.)
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, 229–671–
2281
VerDate Mar<15>2010
17:07 Nov 01, 2013
Jkt 232001
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609
Fortes Laboratories, Inc., 25749 SW.
Canyon Creek Road, Suite 600,
Wilsonville, OR 97070, 503–486–1023
Gamma-Dynacare Medical
Laboratories,* A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986,
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984,
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group)
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–8042/
800–233–6339, (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center)
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845,
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088
National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield, CA
93304, 661–322–4250/800–350–3515
One Source Toxicology Laboratory, Inc.,
1213 Genoa-Red Bluff, Pasadena, TX
77504, 888–747–3774, (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory)
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
66035
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942, (Formerly: Centinela
Hospital Airport Toxicology
Laboratory)
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509–755–8991/
800–541–7891x7
Phamatech, Inc., 10151 Barnes Canyon
Road, San Diego, CA 92121, 858–643–
5555
Quest Diagnostics Incorporated, 1777
Montreal Circle, Tucker, GA 30084,
800–729–6432, (Formerly: SmithKline
Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216,
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
Quest Diagnostics Incorporated, 8401
Fallbrook Ave., West Hills, CA 91304,
818–737–6370, (Formerly: SmithKline
Beecham Clinical Laboratories)
Redwood Toxicology Laboratory, 3650
Westwind Blvd., Santa Rosa, CA
95403, 707–570–4434
South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend,
IN 46601, 574–234–4176 x1276
Southwest Laboratories, 4625 E. Cotton
Center Boulevard, Suite 177, Phoenix,
AZ 85040, 602–438–8507/800–279–
0027
STERLING Reference Laboratories, 2617
East L Street, Tacoma, Washington
98421, 800–442–0438
Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop
70 West, Suite 208, Columbia, MO
65203, 573–882–1273
U.S. Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
E:\FR\FM\04NON1.SGM
04NON1
66036
Federal Register / Vol. 78, No. 213 / Monday, November 4, 2013 / Notices
2002 (Pub. L. 107–296) established this
requirement. This notice and request for
comments is required by the Paperwork
Reduction Act of 1995 (Pub. L. 104–13,
44 U.S.C. Chapter 35).
DATES: Comments are encouraged and
will be accepted until December 4,
2013.
through the use of appropriate
automated, electronic, mechanical, or
other technological collection
techniques or other forms of information
technology, e.g., permitting electronic
submissions of responses.
DEPARTMENT OF HOMELAND
SECURITY
Interested persons are
invited to submit comments, identified
by docket number DHS–2013–0028, by
one of the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Please follow the
instructions for submitting comments.
• Email: Kathy.Higgins@hq.dhs.gov.
Please include docket number DHS–
2013–0028 in the subject line of the
message.
• Fax: (202) 254–6171. (Not a toll-free
number).
• Mail: Science and Technology
Directorate, ATTN: Chief Information
Officer—Rick Stevens, 1120 Vermont
Ave, Mail Stop 0202, Washington, DC
20005.
[Docket No. DHS–2013–0028]
FOR FURTHER INFORMATION CONTACT:
(1) Type of Information Collection:
Renewal of Information Collection.
(2) Title of the Form/Collection: First
Responders Community of Practice:
User Registration Form.
(3) Agency Form Number, if any, and
the applicable component of the
Department of Homeland Security
sponsoring the collection: DHS Science
& Technology Directorate, R-Tech
(RTD), DHS Form 10059 (09/09).
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Individuals; the data will be
gathered from individual first
responders who wish to participate in
the First Responders Community of
Practice.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond:
a. Estimate of the total number of
respondents: 2000.
b. An estimate of the time for an
average respondent to respond: 0.5
burden hours.
c. An estimate of the total public
burden (in hours) associated with the
collection: 1000 burden hours.
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on April 30, 2010 (75 FR
22809). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program.
Janine Denis Cook,
Chemist, Division of Workplace Programs,
Center for Substance Abuse Prevention,
SAMHSA.
[FR Doc. 2013–26276 Filed 11–1–13; 8:45 am]
BILLING CODE 4160–20–P
Agency Information Collection
Activities: Submission for Review;
Information Collection Extension
Request for the DHS S&T First
Responders Community of Practice
Program
Science and Technology
Directorate, DHS.
ACTION: 30-day Notice and request for
comment.
AGENCY:
The Department of Homeland
Security (DHS) invites the general
public to comment on the data
collection form for the DHS Science &
Technology (S&T) First Responders
Community of Practice (FRCoP): User
Registration Page (DHS Form 10059 (9/
09)). The FRCoP web based tool collects
profile information from first responders
and select authorized non-first
responder users to facilitate networking
and formation of online communities.
All users are required to authenticate
prior to entering the site. In addition,
the tool provides members the
capability to create wikis, discussion
threads, blogs, documents, etc., allowing
them to enter and upload content in
accordance with the site’s Rules of
Behavior. Members are able to
participate in threaded discussions and
comment on other member’s content.
The DHS S&T FRCoP program is
responsible for providing a collaborative
environment for the first responder
community to share information, best
practices, and lessons learned. Section
313 of the Homeland Security Act of
TKELLEY on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:07 Nov 01, 2013
Jkt 232001
ADDRESSES:
DHS
FRCoP Contact Kathy Higgins (202)
254–2293 (Not a toll free number).
SUPPLEMENTARY INFORMATION: DHS S&T
currently has approval to collect
information utilizing the User
Registration Form until September 30,
2012 with OMB approval number 1640–
0016. The User Registration Form will
be available on the First Responders
Community of Practice Web site found
at [https://
communities.firstresponder.gov/]. The
user will complete the form online and
submit it through the Web site.
The Department is committed to
improving its information collection
and urges all interested parties to
suggest how these materials can further
reduce burden while seeking necessary
information under the Paper Reduction
Act.
DHS is particularly interested in
comments that:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(2) Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(3) Suggest ways to enhance the
quality, utility, and clarity of the
information to be collected; and
(4) Suggest ways to minimize the
burden of the collection of information
on those who are to respond, including
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
Overview of This Information
Collection
Dated: September 27, 2013.
Rick Stevens,
Chief Information Officer for Science and
Technology.
[FR Doc. 2013–26259 Filed 11–1–13; 8:45 am]
BILLING CODE 9110–9F–P
DEPARTMENT OF HOMELAND
SECURITY
Office of the Secretary
Exercise of Authority Under the
Immigration and Nationality Act
Office of the Secretary, DHS.
Notice of determination.
AGENCY:
ACTION:
Authority: 8 U.S.C. 1182(d)(3)(B)(i).
Following consultations with the
Secretary of State and the Attorney
General, I hereby conclude, as a matter
of discretion in accordance with the
authority granted to me by section
212(d)(3)(B)(i) of the Immigration and
Nationality Act (INA), 8 U.S.C.
1182(d)(3)(B)(i), as amended, as well as
the foreign policy and national security
E:\FR\FM\04NON1.SGM
04NON1
]]>Agencies
[Federal Register Volume 78, Number 213 (Monday, November 4, 2013)]
[Notices]
[Pages 66034-66036]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-26276]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories and Instrumented Initial Testing
Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing
For Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
federal agencies of the Laboratories and Instrumented Initial Testing
Facilities (IITF) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory Guidelines were first published
in the Federal Register on April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal Register on June 9, 1994 (59 FR
29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and
on April 30, 2010 (75 FR 22809).
A notice listing all currently certified laboratories and IITF is
published in the Federal Register during the first week of each month.
If any laboratory or IITF certification is suspended or revoked, the
laboratory or IITF will be omitted from subsequent lists until such
time as it is restored to full certification under the Mandatory
Guidelines.
If any laboratory or IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the Internet at https://www.workplace.samhsa.gov.
FOR FURTHER INFORMATION CONTACT: Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 7-1051, One Choke Cherry Road, Rockville,
Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially
developed in accordance with Executive Order 12564 and section 503 of
Public Law 100-71. The ``Mandatory Guidelines for Federal Workplace
Drug Testing Programs,'' as amended in the revisions listed above,
requires strict standards that laboratories and Instrumented Initial
Testing Facilities (IITF) must meet in order to conduct
[[Page 66035]]
drug and specimen validity tests on urine specimens for federal
agencies.
To become certified, an applicant Laboratory or IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a Laboratory or IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and IITF in the applicant stage of certification are
not to be considered as meeting the minimum requirements described in
the HHS Mandatory Guidelines. A Laboratory or IITF must have its letter
of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests
that it has met minimum standards.
In accordance with the Mandatory Guidelines dated November 25, 2008
(73 FR 71858), the following Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the minimum standards to conduct drug
and specimen validity tests on urine specimens:
Instrumented Initial Testing Facilities (IITF)
None.
Laboratories
ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-
7840/800-877-7016, (Formerly: Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624,
585-429-2264
Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210, 615-
255-2400, (Formerly: Aegis Sciences Corporation, Aegis Analytical
Laboratories, Inc.)
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823, (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little Rock,
AR 72209-7056, 501-202-2783, (Formerly: Forensic Toxicology Laboratory
Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802, 800-
445-6917
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229-
671-2281
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609
Fortes Laboratories, Inc., 25749 SW. Canyon Creek Road, Suite 600,
Wilsonville, OR 97070, 503-486-1023
Gamma-Dynacare Medical Laboratories,* A Division of the Gamma-Dynacare
Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A
1P4, 519-679-1630
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center)
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845, (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.)
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304, 661-322-4250/800-350-3515
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504, 888-747-3774, (Formerly: University of Texas Medical Branch,
Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory)
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology
Laboratory)
Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane,
WA 99204, 509-755-8991/800-541-7891x7
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858-
643-5555
Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084,
800-729-6432, (Formerly: SmithKline Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403,
610-631-4600/877-642-2216, (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA
91304, 818-737-6370, (Formerly: SmithKline Beecham Clinical
Laboratories)
Redwood Toxicology Laboratory, 3650 Westwind Blvd., Santa Rosa, CA
95403, 707-570-4434
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South
Bend, IN 46601, 574-234-4176 x1276
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602-438-8507/800-279-0027
STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington
98421, 800-442-0438
Toxicology & Drug Monitoring Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO
65203, 573-882-1273
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085
* The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
[[Page 66036]]
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory Guidelines
published in the Federal Register on April 30, 2010 (75 FR 22809).
After receiving DOT certification, the laboratory will be included in
the monthly list of HHS-certified laboratories and participate in the
NLCP certification maintenance program.
Janine Denis Cook,
Chemist, Division of Workplace Programs, Center for Substance Abuse
Prevention, SAMHSA.
[FR Doc. 2013-26276 Filed 11-1-13; 8:45 am]
BILLING CODE 4160-20-P
